Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials

Pharmacogenomics

Volumn 20, Issue 1, 2019, Pages 37-47

  Bousman, Chad A ^a,b,c   Arandjelovic, Katarina ^d   Mancuso, Serafino G ^e   Eyre, Harris A ^d,e,f,g   Dunlop, Boadie W ^h  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA CHILDREN S HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d DEAKIN UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f EAST TEXAS MEDICAL CENTER   (United States)

^g CNSDose LLC   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Clinical decision support; Depression; Genetic; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ANTIDEPRESSANT AGENT;

ARTICLE; CYP2C19 GENE; CYP2D6 GENE; DECISION SUPPORT SYSTEM; DEPRESSION; GENE; GENE IDENTIFICATION; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETIC TESTING; REMISSION; SYSTEMATIC REVIEW; ANIMAL; GENETICS; MAJOR DEPRESSION; META ANALYSIS; PHARMACOGENETICS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85058346228     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2018-0142     Document Type: Article

References (51)

1. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust. N. Z. J. Psychiatry 49(12), 1087-1206 (2015).
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STARD report. Am. J. Psychiatry 163(11), 1905-1917 (2006).
3. Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int. Clin. Psychopharmacol. 25(4), 189-198 (2010).
4. Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry 2, e172 (2012).
5. Jain FA, Hunter AM, Brooks JO 3rd, Leuchter AF. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress. Anxiety 30(7), 624-630 (2013).
6. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol. Psychiatr. 73(7), 679-682 (2013).
7. Crisafulli C, Fabbri C, Porcelli S, et al. Pharmacogenetics of antidepressants. Front. Pharmacol. 2, 6 (2011).
8. Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3(6), 585-590 (2016).
9. Bousman CA, Forbes M, Jayaram M, et al. Antidepressant prescribing in the precision medicine era: A prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17(1), 60 (2017).
10. Winner JG, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: A perspective on context and implications on clinical utility. Yale J. Biol. Med. 88(4), 375-382 (2015).
11. Benitez J, Jablonski MR, Allen JD, Winner JG. The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes. Appl. Transl. Genom. 5, 47-49 (2015).
12. Hornberger J, Li Q, Quinn B. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am. J. Manag. Care 21(6), e357-365 (2015).
13. Brennan FX, Gardner KR, Lombard J, et al. a naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim. Care Companion CNS Disord. 17(2), (2015).
14. Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am.J. Psychiatry 175(9), 873-886 (2018).
15. de Leon J, Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy Expert Rev. Clin. Pharmacol. 9(3), 351-354 (2016).
16. Singh AB, Bousman CA. Antidepressant pharmacogenetics. Am. J. Psychiatry 174(5), 417-418 (2017).
17. Bousman C, Allen J, Eyre HA. Pharmacogenetic tests in psychiatry. Am. J. Psychiatry 175(2), 189 (2018).
18. Rahman T, Ash DM, Lauriello J, Rawlani R. Misleading guidance from pharmacogenomic testing. Am. J. Psychiatry 174(10), 922-924 (2017).
19. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339, b2700 (2009).
20. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Hoboken, NJ, USA (2011).
21. Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R . Springer, Switzerland (2015).
22. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J. Stat Softw. 36(3), 1-48 (2010).
23. Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med. Res. Methodol. 11, 41 (2011).
24. Novianti PW, Roes KC, van der Tweel I. Estimation of between-trial variance in sequential meta-analyses: A simulation study. Contemp. Clin. Trials 37(1), 129-138 (2014).
25. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An update. Contemp. Clin. Trials 28(2), 105-114 (2007).
26. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res. Synth. Methods 1(2), 112-125 (2010).
27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stats. Med. 21(11), 1539-1558 (2002).
28. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 85(3), 415-424 (2000).
29. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J. Royal Stat. Soc. Ser. A 172(1), 137-159 (2009).
30. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 333(7568), 597-600 (2006).
31. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98(2), 127-134 (2015).
32. Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102(1), 37-44 (2016).
33. Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96, 100-107 (2017).
34. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psychopharmacol. Neurosci. 13(2), 150-156 (2015).
35. Pérez V, Salavert A, Espadaler J, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1), 250 (2017).
36. Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3(6), 585-590 (2016).
37. Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Prog. Neuropsychopharmacol. Biol. Psychiatry 86, 36-44 (2018).
38. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst. Rev. 2, MR000033 (2017).
39. Peterson K, Dieperink E, Anderson J, Boundy E, Ferguson L, Helfand M. Rapid evidence review of the comparative effectiveness, harms, cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 234(11), 1649-1661 (2017).
40. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder A systematic review of clinical trials and cost-effectiveness studies. J. Clin. Psychiatry 78(6), 720-729 (2017).
41. Greden J, Parikh S, Rothschild A, et al. Combinatorial pharmacogenetics significantly improves response and remission for major depressive disorder: A large, blinded, randomized controlled trail. In: American Psychiatric Association Annual Meeting. American Psychiatric Association, New York, NY, USA (2018).
42. Fields ES, Lorenz RA, Winner JG. Use of combinatorial pharmacogenomic testing in two cases from community psychiatry. Pharmacogenom. Pers. Med. 9, 79-84 (2016).
43. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 16(89), 219-227 (2013).
44. Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet. Genomics 27(11), 387-393 (2017).
45. Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: A systematic review. second update of the literature. PLoS ONE 11(1), e0146262 (2016).
46. Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: Combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 39(3), 592-602 (2017).
47. Bousman C, Dunlop B. Genotype, phenotype, medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. In Press (2018).
48. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 12(3), 197-204 (2012).
49. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: Results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012).
50. Walden LM, Brandl EJ, Changasi A, et al. Physicians' opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 229(3), 913-918 (2015).
51. McKillip RP, Borden BA, Galecki P, et al. Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program. Clin. Pharmacol. Ther. 102(1), 106-114 (2016).